Article: U.S. Food And Drug Administration Licenses INFANRIX(TM) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)

-- Only acellular DTP vaccine proven more effective than whole-cell DTP --

 
-- To be distributed by SmithKline Beecham Pharmaceuticals -- 

PHILADELPHIA, Jan. 30 /PRNewswire/ -- SmithKline Beecham (SB) announced today that the U.S. Food and Drug Administration has granted a license to SmithKline Beecham Biologicals to manufacture INFANRIX(TM) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed). INFANRIX is indicated for active immunization against diphtheria, tetanus and pertussis (whooping cough) in infants and children 6 weeks to 7 years of age (prior to seventh birthday). The vaccine will be distributed by SmithKline ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!